-transparent.png){kind=logo}
The interaction between GABAA receptors and benzodiazepine (BZD) recognition site subtypes in the spinal cord of the rat was investigated. Computer analysis of displacement curves for [3H]flunitrazepam [( 3H]FNT) binding by 2-oxo-quazepam (2OXOQ) indicated the presence of two subtypes of BZD recognition sites in this region. Type I sites accounted for approximately 25% of the total number of BZD recognition sites, the remainder being Type II sites. A similar proportion of Type I and Type II sites was obtained by Scatchard analysis of the saturation curves for [3H]FNT, [3H]2OXOQ and [3H]ethyl-beta-carboline-3-carboxylate [( 3H]beta CCE) binding. The in vitro addition of GABA (10(-8)-10(-4) M) to spinal cord membrane preparations produced an increase in the binding of [3H]FNT and [3H]2OXOQ. The maximal enhancement produced by GABA was 50 and 82% above control values for [3H]FNT and [3H]2OXOQ, respectively. In contrast, GABA stimulated both [3H]FNT and [3H]2OXOQ binding in the cerebellum to a similar extent. We also evaluated the effects of different ligands for BZD recognition sites on the binding of [3H]GABA to spinal cord membranes, as compared with brain areas containing a higher proportion ( greater than 30%) of Type I sites. Diazepam, quazepam and the beta-carboline, ZK 93423, enhanced the specific binding of [3H]GABA in a concentration-dependent manner (10(-7)-10(-5) M) in the cerebral cortex and hippocampus but not in the spinal cord and cerebellum. These results indicate that there is a regional variation in the interaction between GABA and BZD recognition sites in the central nervous system.
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
December 1988,
Pharmacological research communications,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
November 1997,
Trends in pharmacological sciences,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
February 1985,
European journal of pharmacology,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
January 1991,
Advances in experimental medicine and biology,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
August 2018,
ACS chemical biology,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
September 2013,
British journal of pharmacology,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
February 1985,
Neuropharmacology,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
August 1983,
Japanese journal of pharmacology,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
January 1997,
Acta neurochirurgica. Supplement,
M G Corda, and
O Giorgi, and
B Longoni, and
E Ongini, and
G Pesce, and
R Cruciani, and
G Biggio
June 1995,
Neuroreport,
